The anticancer properties of DOX-loaded CP-PPA, CPS-HMP, CROSS-CP-PPA, and CROSS-CPS-HMP NPs were evaluated against breast cancer MCF-7 cells, which are widely used for assessing DOX drug delivery systems (Naruphontjirakul and Viravaidya-Pasuwat, 2019; Zhong et al., 2019). This evidence concerns the gene CP and breast carcinoma.